EU Regulator Backs Eisai-Biogen Alzheimer's Drug after Initial Rejection

2023-01-20T224759Z_1083470858_RC2F2W9147J4_RTRMADP_3_EISAI-BIOGEN-ALZHEIMERS-FDA
The European Union’s drugs regulator on Thursday recommended approval of Eisai 4523.T and Biogen’s BIIB.O Leqembi for some patients with early Alzheimer’s disease, reversing its initial decision from four months ago.

New contents